-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Guided reading
Active surveillance (AS) is an alternative to curative treatment options (surgery, radiotherapy, etc.
To resolve these controversies, a Dutch research team conducted this evidence-based study
We included all prospective and retrospective studies related to AS based on the Priority Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement
The researchers screened 333 studies from 17,011 literatures and extracted 375 AS protocols
Based on this SR, for AS protocols without MRI, the investigators recommend: (1) Low-risk patients with International Society of Urology Pathology Classification (ISUP) 2, or a single intermediate-risk factor (excluding ISUP 3) (2) Patients with low-risk but more extensive involvement (number of positive needles ≥ 3 or CI > 50%) PCa patients in ISUP grade 1 should be closely monitored, while similar patients in ISUP grade 2 should be closely monitored.
references:
Willemse PM, Davis NF, Grivas N, et al.
END